Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.
You may also be interested in...
More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator
More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator
More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
Biotech will seek to win approval in CF patients with G551D mutation, then demonstrate broader application within the disease.